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The lack of selectivity of conventional antitumour drugs against cancer cells is responsible for their high toxicity. The development of
new tumour-specific drugs is therefore highly needed. We tested the cytotoxic effects and the nature of cell death induced by a
naturally dimeric bovine RNase and a newly engineered dimeric human RNase upon three genetically well-defined normal and
malignant thyroid cell systems. RNases effects were compared with those of doxorubicin, a conventional antineoplastic drug. Our
results show significant and selective proapoptotic effects exerted on tumour cells by both RNases, the strength of their cytotoxic
and apoptotic activity being directly related to the degree of cell malignancy. No toxic effects were observed upon normal cells.
Doxorubicin showed, instead, cytotoxic and apoptotic effects also against normal cells. The in vitro results were corroborated by the
antitumour action of both dimeric RNases towards a malignant human thyroid tumour grown in nude mice. These results indicate a
selective action of dimeric RNases against cancer cells and suggest the potential application of these molecules or their derivatives to
the treatment of aggressive subtypes of thyroid cancer.
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Most of the known conventional antineoplastic drugs lack
specificity against cancer cells, exerting instead unfavourable
reactions in cancer patients due to their toxic effects on normal
tissues (Hurley, 2002). Recent advances in cancer molecular
biology allowed the discovery of discrete molecular lesions in
key proteins responsible for the development of a fully aggressive
cancer phenotype (Chabner et al, 1998; Gibbs, 2000). These
advances have in turn led to the development of new anticancer
drugs possessing selective activity towards tumour cells bearing
those specific genetic lesions (Gibbs, 2000; Bange et al, 2001). By
this approach, a successful treatment can be achieved only in those
types of tumours bearing the genetic lesion specifically targeted by
the drug.
Some ribonucleases are endowed with a strong antineoplastic
activity. The best known members of this family are onconase, a
protein extracted from Rana pipiens and currently tested in phase
II and III clinical trials (Wu et al, 1993; Juan et al, 1998; Halicka
et al, 2000, 2002; Lee et al, 2000; Mikulski et al, 2002; Saxena et al,
2002), and seminal ribonuclease, extracted from bull semen (BS-
RNase) (Youle and D’Alessio, 1997). BS-RNase, the only dimeric
member of the pancreatic-type RNase superfamily (Beintema et al,
1997), is endowed with a strong cytotoxic activity against tumour
cells in vitro (Laccetti et al, 1992) and is active against cancer cells
in vivo, as well (Laccetti et al, 1994). Through protein engineering,
a new dimeric RNase of human nature, HHP2-RNase, has been
derived from human pancreatic RNase (HP-RNase). This was
achieved by replacing five HP-RNase amino-acid residues (Q28,
K31, K32, N34, E111) with the corresponding residues (L28, C31,
C32, K34, G111) from BS-RNase. HHP2-RNase was even more
powerful as a cytotoxic agent than BS-RNase, and as selective for
malignant cells (Piccoli et al, 1999; Di Gaetano et al, 2001). This
protein has the obvious advantage over BS-RNase of being little or
not immunogenic at all for humans.
The exact mechanism of the antitumour action of RNases
remains to be clarified. The binding of BS-RNase to a component
of the extracellular matrix (Mastronicola et al, 1995) and of
onconase to an unidentified cell surface receptor (Wu et al, 1993)
is followed by endocytosis, translocation to the cytosol, degrada-
tion of RNA (rRNA or tRNA by BS-RNase and onconase,
respectively) and suppression of protein synthesis leading to cell
death. BS-RNase is internalised and enclosed in endosomes in both
normal and malignant cells. Only in malignant cells, however, the
RNase is transported into the trans Golgi network, whence it is
released in the cytosol (Bracale et al, 2002). The dimeric structure
of BS-RNase and HHP2-RNase is essential to enter the cytosol
(Murthy et al, 1996; Antignani et al, 2001; Leland et al, 2001). The
cytosolic ribonuclease inhibitor (cRI) tightly binds to internalised
ribonucleases, thus blocking their cytotoxic activity; only ribonu-
cleases that can evade cRI are capable of exerting a cytotoxic
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saction. Also, the resistance of BS-RNase to cRI inhibition depends
on the dimeric structure of the enzyme (Murthy et al, 1996;
Antignani et al, 2001; Leland et al, 2001). On the other hand,
onconase, the frog ribonuclease, is inhibited by frog but not
mammalian cRI.
To verify whether the antineoplastic activity of ribonucleases
was exerted on malignant cells independently from their specific
genetic lesions, we performed a systematic study of the effects of
BS-RNase and HHP2-RNase against genetically well-defined
systems of thyroid tumour cells. Thyroid tumours are the most
prevalent endocrine malignancy and some subtypes, anaplastic
and poorly differentiated carcinomas, are associated with sig-
nificant morbidity and mortality (Hedinger et al, 1989). Three
different cell systems were used, derived from rat (Ambesi-
Impiombato et al, 1980; Fusco et al, 1987; Portella et al, 1989) or
human thyroid follicular cells (Kantor et al, 1978; Pang et al, 1989;
Ishizaka et al, 1990; Gioanni et al, 1991; Curcio et al, 1994 and
carrying as diverse genetic alterations as a gain-of-function of Ki-
ras,N -ras, src, ret/ptc1 or B-Raf oncogenes or loss-of-function of
p53. These cells display a full spectrum of progressive malignancy
from normal differentiated, to immortalised, to oncogene-trans-
formed, and to tumour- and metastasis-derived cells.
We show that HHP2-RNase and BS-RNase are highly cytotoxic
for all tested tumour cell lines regardless of the specific genetic
lesion carried by the target cells. Their activity was directly related
to the degree of cell malignancy with no effects on the growth of
normal cells. In stark contrast, doxorubicin showed its maximal
cytotoxic effects against normal cells. A strong inhibitory activity
was exerted by both RNases on the growth of tumours induced in
nude mice, following subcutaneous (s.c.) injection of human
thyroid carcinoma cells. The dimeric nature of the RNases scored
essential for the antineoplastic effects, as no cytotoxic activity was
exerted by monomeric RNases. These results suggest the potential
utilisation of dimeric RNases for the therapy of aggressive human
thyroid tumours, known to respond poorly to conventional
chemotherapeutics.
MATERIALS AND METHODS
Cell lines
FRTL-5 is a normal, differentiated rat thyroid epithelial cell line
(Ambesi-Impiombato et al, 1980). FRTL-5-v-src and FRTL-5-v-Ki-
ras are in vitro v-src- and v-Ki-ras-transformed FRTL-5 cells
(Fusco et al, 1987). TK-6 and MPTK-6 were derived from primary
thyroid carcinomas and lung metastasis, respectively, induced in
rats by the intrathyroid injection of the Kirsten Murine Sarcoma
Virus (Portella et al, 1989). P5 is a primary culture of normal
human differentiated thyrocytes (Curcio et al, 1994). HDF cells are
normal human diploid fibroblasts (Kantor et al, 1978). The four
human thyroid carcinoma-derived cell lines were Cal62 and ARO
cells from anaplastic carcinomas (Pang et al, 1989; Gioanni et al,
1991) and NPA and TPC1 cells from papillary carcinomas (Pang
et al, 1989; Ishizaka et al, 1990). Rat and human cell lines were
cultured as previously reported (Kantor et al, 1978; Ambesi-
Impiombato et al, 1980; Fusco et al, 1987; Pang et al, 1989; Portella
et al, 1989; Ishizaka et al, 1990; Gioanni et al, 1991; Curcio et al,
1994).
Cell survival
At day 0, 100–500 cells (depending on the cell line) were plated.
After 1 day, cells were treated for 24h with increasing amounts of
either ribonuclease (from 1.37ngml
 1 to 13.7mgml
 1) or doxor-
ubicin (from 29pgml
 1 to 290ngml
 1) corresponding to final
concentrations for both drugs ranging from 0.05 to 500nM. After
2–3 weeks, colonies were stained with crystal violet and counted,
as previously described (Spalletti-Cernia et al, 1995).
Gel electrophoresis of fragmented DNA
Agarose gel electrophoresis was performed as described by
Hockenbery et al (1990). Briefly, DNA from control and treated
cells (1 10
6 cells) was extracted with phenol–chloroform,
precipitated and subjected to electrophoresis on a 1.2% agarose
gel. The agarose gel was stained with ethidium bromide and the
resulting DNA fragmentation pattern was visualised by UV
illumination.
Fluorescence analysis of apoptosis
Cells were plated on coverglasses in 24-well plates and 24h later,
the RNase under test was added to a final concentration of 1.8.mM.
Following 72h of treatment, cells were fixed in 3.7% formaldehyde
in PBS for 15min at room temperature. Cells were then
permeabilised with 0.1% Triton X-100 for 5min at room
temperature and stained for 30min with Hoechst 33258 (Sigma
Chemical Co.) at a concentration of 0.5mgml
 1 in PBS. The stained
cells were observed under an epifluorescent microscope (Axiovert
2, Zeiss) as previously reported (Piccoli et al, 1999).
In vivo experiments
Nude mice (5 weeks old) were injected s.c. at day 0 with 1 10
6
ARO cells (Pang et al, 1989). Mice were then treated with six
injections in the peritumoral areas of 20mgg
 1 of body weight of
RNases. The first injection was given 24h after the cells’
implantation. The site of injection was marked. The subsequent
administrations were repeated at 72h intervals. During the period
of treatment, tumour volume (V) was calculated by the following
formula: V¼width
2 length 0.5 (Yanase et al, 1993). At day 22,
all animals were killed and the tumours were excised and weighed.
Animal studies were conducted in accordance with the Italian
regulation for experimentation on animals (Workman et al, 1998).
All in vivo experiments were carried out with ethical committee
approval and met the standards required by the UKCCCR
guidelines. No mice showed signs of wasting or other signs of
toxicity.
Substances
BS-RNase was purified from bovine seminal vesicles as previously
reported (D’Alessio et al, 2001). HHP2-RNase and HP-RNase were
prepared and purified as described (Di Gaetano et al, 2001).
Doxorubicin and RNase A were purchased from Sigma Chemical
Co. (St Louis, MO, USA). All chemicals used were of reagent grade.
The disposable materials used for cell culture were from Nunc
(Mascia-Brunelli, Milano, Italy). Nude mice were purchased from
Charles River Italia (Calco, Italy).
RESULTS
Selective cytotoxicity of BS-RNase and HHP2-RNase for
thyroid cancer cells
The experiments reported in this paper were aimed at: (i) testing
the possibility that the strength of the antineoplastic action of
ribonucleases could be directly correlated with the degree of
tumour cell malignancy; (ii) comparing the effects of RNases with
those of doxorubicin, a conventional anticancer drug. This has
been made possible by the use of rat and human cell systems,
carrying well-characterised genetic lesions and displaying pro-
gressively increasing malignancy. All the used cell models refer to a
specific epithelial tumour type, that is, carcinomas derived from
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sthyroid epithelial follicular cells. The main biological properties of
cell lines are summarised in Table 1, where they are subdivided
into three different sets. The first one is represented by normal rat
thyroid follicular FRTL-5 cells, which maintain the differentiated
phenotype (Ambesi-Impiombato et al, 1980) and their in vitro
transformed derivatives (FRTL-5 v-src and v-Ki-ras) obtained by
retroviral transduction (Fusco et al, 1987). The second set is
represented by TK-6 and MPTK-6, established in culture from
primary thyroid carcinoma and lung metastasis, respectively, of
rats subjected to intrathyroid injection of the v-Ki-ras-carrying
retrovirus (Portella et al, 1989). The third set comprised normal
human differentiated P5 thyrocytes (Curcio et al, 1994), normal
human primary HDF fibroblasts, two papillary carcinoma-derived
(TPC1 and NPA) and two anaplastic carcinoma-derived cell lines
(Cal62 and ARO). The NPA cell line carries a double deletion of the
p53 gene and an activating V599E point mutation in the B-Raf
oncogene (Fagin et al, 1996; Kimura et al, 2003). Cal62 and ARO
cells carry a mutated form of p53; the Cal62 cell line carries, in
addition, a mutated N-ras gene (Namba et al, 1990; Fagin et al,
1993; Salvatore et al, 1996; Vecchio and Santoro, 2000). TPC1 cells
carry a paracentric inversion of chromosome 10 causing the
recombination of the tyrosine kinase-encoding domain of the ret
receptor to the 50-terminal region of the H4 gene, leading to the
generation of the ret/ptc1 oncogene (Ishizaka et al, 1990), a lesion
commonly found in papillary carcinomas (Grieco et al, 1990).
We compared cell growth properties, colony-forming efficiency
in soft agar and tumorigenicity upon s.c. injection in nude mice of
the various cell lines; the results are reported in Table 1. Normal
FRTL-5, P5 and HDF cells and thyroid papillary carcinoma-
derived TPC1 cells did not show malignant features. TK-6 and
FRTL-5-v-src cells showed an intermediate degree of malignancy,
being able to grow in a semisolid medium and to induce tumours
with long latency. MPTK-6, FRTL-5-v-Ki-ras, Cal 62, NPA and
ARO cells displayed a highly malignant phenotype, as shown by
their great efficiency to form colonies in soft agar and to induce
tumours with short latency in nude mice (Table 1).
We tested the effects of BS-RNase and HHP2-RNase on all these
cell lines in comparison to doxorubicin. Sensitivity to the
compounds was expressed as IC50 (the concentration inhibiting
50% of the colony-forming efficiency) and is reported in Table 1.
IC50 values were determined from the curves (Figure 1) obtained
by plotting the colony-forming efficiency vs the logarithm of drug
molarity (the curves for P5, NPA and Cal62 are not shown). The
results demonstrated a selective cytotoxicity of the two dimeric
RNases towards cancer cells, the strength of the activity being
directly related to the malignant phenotype of tumour cells. The
most malignant cells (MPTK-6, FRTL-5-v-Ki-ras, NPA, Cal 62 and
ARO) showed the lower values of IC50 (Table 1). No toxic effects
were observed on normal counterparts of all cell systems. In
contrast, an inverse relationship was observed between doxor-
ubicin cytotoxicity and the degree of cell malignancy, the activity
of doxorubicin being maximal against the normal cells (FRTL-5,
HDF and P5 cells) (Table 1, Figure 1).
BS-RNase and HHP2-RNase induce apoptosis in tumour
cells
We investigated the nature of cell death induced by treatment with
RNases. Cells were analysed for the presence of fragmented DNA
with the characteristic pattern of internucleosomal ladder,
suggestive of apoptosis. As shown in Figure 2, treatment with
BS-RNase and HHP2-RNase, 72h at 1.8mM (50mgml
 1), selectively
promoted apoptosis in tumorigenic cells (MPTK-6, FRTL-5-v-Ki-
ras, NPA and ARO cells), whereas apoptosis was undetected in the
normal cell counterparts (FRTL-5 and HDF cells). Doxorubicin,
instead (1.8mM, i.e. 1mgml
 1, for 24h), promoted apoptosis in
normal cells and not in tumour cells. After 72h of treatment,
doxorubicin killed all cells, malignant and nonmalignant (not
shown). No proapoptotic activity was exerted by monomeric
RNases (RNase A and HP-RNase) (Figure 2).
The presence of apoptotic nuclear bodies was analysed by a
fluorescence microscopy after staining with Hoechst 33258
(Figure 3). In these experiments, we utilised the human cell line
displaying the most malignant phenotype (ARO cell line). When
this cell line was treated with either dimeric ribonuclease, it
showed the characteristic chromatin condensation and margina-
tion and many fragmented nuclei. Again, monomeric RNase A and
HP-RNase treatment did not cause any change in the nuclear
morphology and number of cells (Figure 3). A quantitative
estimation of BS-RNase- and HHP2-RNase-induced apoptosis
Table 1 Biological properties of the thyroid-derived cell lines used in this study and their sensitivity to doxorubicin and RNases
Antitumour agent IC50
c
Cell line Genetic lesion Doubling time (h) CFE
a Tumour incidence
b Latency Dox. BS HHP2
In vitro transformed rat cells
FRTL-5 33 0 0 1.5 4500 4500
FRTL-5-v-src v-src 28 20 85 3 weeks 40 100 250
FRTL-5-v-Ki-ras v-Ki-ras 14 49 100 5 days 200 10 18
Tumour- and metastasis-derived rat cells
TK-6 v-Ki-ras 24 34 100 2.5 weeks 180 15 30
MPTK-6 v-Ki-ras 16 74 100 7–10 days 300 10 10
Human cells
P5 — 58 0 0 — 0.9 4500 4500
HDF — 36 0 0 — 2 4500 4500
TPC1 ret/ptc1 26 1 0 — 5 140 320
Cal 62 p53
*;N - ras 24 20 100 7 days Not done 74 37
NPA p53 / ; B-raf
* 13 82 100 20 days 300 5 5
ARO p53
* 10 92 100 4 days 280 60 61
aColony-forming efficiency was measured in agar and calculated by the formula: (number of colonies formed/number of plated cells)  100. Colonies larger than 64 cells were
scored after 2–3 weeks.
bTumorigenicity was assayed by injecting 10
6 cells into either nude mice or syngenic rats. The incidence (%) was calculated as the per cent of animals
with tumours over the total number of animals tested.
cThe inhibiting concentration values (IC50) were determined by the colony-forming assay and are expressed as nM
concentrations. Values are means7s.d. of triplicate determinations from three independent experiments.
*Presence of a mutated protein.
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sgave values of 70720 and 90720%, respectively, of apoptotic cells.
Similar results were obtained when the NPA cell line was used
(data not shown).
Antitumoral effects of BS-RNase and HHP2-RNase in nude
mice
We utilised ARO cells, characterised by a very short latency period
for tumour growth in mice, to assess the antineoplastic activity of
ribonucleases in vivo in mice bearing human thyroid neoplastic
cells. Nude mice, inoculated with 1 10
6 ARO cells s.c., were
treated with six injections in the peritumoral area of BS-RNase or
HHP2-RNase (20mgg
 1 of body weight). Administrations were
repeated at 72h intervals. A group of control mice was treated with
pancreatic RNase A with the same protocol and dose; another
control group was injected with PBS alone. As shown in Figure 4,
the antitumoral effects of both BS-RNase and HHP2-RNase were
clearly evident during the whole period of mice treatment. In
particular, the latency period for tumour appearance was highly
prolonged in treated mice, reaching 14 and 18 days, respectively.
At the end of the experiment, the average weight of the tumours
from mice treated with BS-RNase and HHP2-RNase was 15 and
10% (85 and 90% of growth inhibition, respectively) with respect
to the average weight of tumours grown in untreated mice or in
mice treated with RNase A.
Finally, we sought to determine the toxicity of BS-RNase in
healthy mice. Six injections intraperitoneal (i.p.) of 20mgg
 1 of
body weight of BS-RNase at 72h intervals did not cause any effects
on the survival of mice. The only side effect was a diminished body
weight (20% reduction) with respect to untreated mice (data not
shown).
DISCUSSION
We have used a well-controlled thyroid cell model system to
demonstrate specificity for malignant cells of the cytotoxic and
proapoptotic effects exerted by two dimeric ribonucleases. The in
vitro results were corroborated by a strong antitumour action of
both RNases against tumours obtained by the injection of
malignant cells in nude mice. Results from Phase II and III
clinical trials in which onconase was used as the antitumour agent
(Juan et al, 1998; Mikulski et al, 2002) support our belief that
certain RNases exert a strong cytotoxicity towards cancer cells
(Mikulski et al, 2002). However, onconase, at variance with the two
ribonucleases that have been used in the present paper, has been
shown to exert a cytotoxic effect also towards noncancerous cells
and, at high concentrations, it leads to renal toxicity in mice
(Haigis et al, 2003). The nature of cell death for both BS-RNase and
HHP2-RNase has been found to be apoptotic. In fact, we have
recently shown that BS-RNase and HHP2-RNase treatment triggers
the activation of the execution caspase-3 (Spalletti-Cernia et al,
2003).
The availability of a genetically well-defined system of thyroid
normal and tumour cells in our laboratory allowed us to perform a
systematic study of the activities of BS-RNase and HHP2-RNase in
comparison with the known chemotherapeutic drug doxorubicin.
The cell systems used are representative of the different degrees of
aggressiveness found in the various human thyroid tumours.
Indeed, human thyroid carcinomas vary from the asymptomatic
microcarcinoma to the differentiated carcinoma, to the anaplastic
carcinomas, one of the most aggressive human cancers (Hedinger
et al, 1989). Doxorubicin alone, and in combination with cisplatin,
is the most widely used therapeutic agent for this last category of
thyroid carcinomas; however, it does not improve survival in
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Figure 1 Cell survival of malignant and nonmalignant cell lines treated with the increasing concentration of doxorubicin, BS-RNase or HHP2-RNase. The
average results7s.d. of three independent determinations. Cells were exposed to each molecule for 24h. After 3 weeks, cell survival was measured by
counting colony-forming units.
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sanaplastic carcinoma patients (Hedinger et al, 1989; Rosai et al,
1992). The findings reported here demonstrate that the strength of
cytotoxic and apoptotic activity of RNases exerted on cells grown
in vitro was directly related to the degree of cell malignancy. On
the contrary, doxorubicin showed its maximal cytotoxic and
apoptotic effect against normal cells.
Unlike doxorubicin, BS-RNase and HHP-2 RNase are not known
to induce, nor do they appear to be influenced by, the multidrug-
resistant phenotype, one of the most important mechanisms
responsible for recurrences and metastatic invasion after che-
motherapy. Indeed, MPTK-6 cells, highly susceptible to RNases,
show the presence of a multidrug-resistant phenotype that is
Markers
Untreated
Doxorubicin
RNase A
BS-RNase
HP-RNase
HHP2-RNase
Markers
Untreated
Doxorubicin
RNase A
BS-RNase
HP-RNase
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FRTL-5 FRTL-5-v-Ki-ras MPTK-6
HDF NPA ARO
Figure 2 Analysis of DNA fragmentation in the malignant and nonmalignant cell lines treated with doxorubicin, BS-RNase or HHP2-RNase. Markers:
molecular weight markers (123-bp multimers). These data are representative of at least three independent experiments.
Figure 3 Fluorescence microscopy analysis of ARO cells treated with RNases. ARO cells were exposed for 72h to the RNase under test (1.8mM). Cells
were fixed and stained with Hoechst 33258 to reveal the nuclear signs of apoptosis and photographed ( 360).
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sindependent from the gp170 glycoprotein (Spalletti-Cernia et al,
1995).
Another important feature is that both RNases exert their
cytotoxicity independent of the genetic lesions present in the target
cancer cells. Here, we show that they exhibit a similar cytotoxic
activity against cells bearing Ki-ras (FRTL5-v-Ki-ras and MPTK-6),
N-ras (Cal62) and B-raf (NPA) mutations as well as against cells
bearing p53 alterations. The most malignant cells, which are highly
sensitive to both RNases, are representative of the whole possible
spectrum of the p53 status. NPA cells show lack of any functional
p53 (Fagin et al, 1996), ARO and Cal62 show a heterozygous
mutant p53 (Fagin et al, 1993), whereas TK-6 and MPTK-6 have a
normally functioning p53 (Vecchio et al, unpublished observa-
tions). Therefore, RNases cytotoxicity is also independent of the
p53 status of the malignant cell line used. This has important
therapeutic implications since it is well known that the majority of
human cancers bear inactive p53 that renders tumour cells unable
to undergo drug-induced apoptosis. In particular, mutations of
p53 are the common feature of anaplastic thyroid cancer (Fagin
et al, 1993). The in vitro results are strengthened by in vivo
experiments in which peritumoral injection of both RNases
inhibited the growth of human anaplastic thyroid cancer cells
transplanted into nude mice and grown s.c. The protocol of
RNases administration 1 day after the implantation of the tumour
cells may seem to be of little applicability in the clinic. However, it
must be considered that the growth rate of the tumour cells
injected in mice is much higher than that in humans. In addition,
nude mice injected with the ARO cells rapidly die if untreated and
their treatment therefore must begin very early after implantation.
For these reasons, 1 day after the s.c. implantation of the tumour
cells in mice could well be considered equivalent to the initial
phase of tumour growth in humans and could coincide with the
beginning of a potential therapy. Moreover, RNase or other
antineoplastic drug administration in the peritumoral area has
been successfully used previously for the treatment of rat (Laccetti
et al, 1994) or human thyroid tumour cells (Carlomagno et al,
2002; Barzon et al, 2002, 2003). Obviously, the applicability of
RNases in clinical situations and the site of administration of the
antitumour molecules would depend largely on the type of the
tumour, on its localisation and on the tumour growth rate.
However, it is important to note that we have already shown that
BS-RNase is capable of exerting a strong antitumour effect even
when administered i.p. in a different in vivo experimental mouse
system (Laccetti et al, 1994). Finally, it is important to underline
that the peritumoral injection of RNase did not cause any adverse
effect, such as death, body weight loss or changes in the physical
appearance or behaviour of the treated mice. This is at variance
with the slightly toxic effect (20% body weight reduction) observed
with i.p. injections of BS-Rnase (see Results section). This further
supports the choice of using peritumoral injections of the
ribonucleases in the experimental system described here.
Furthermore, it must be considered that, in particular, human
anaplastic thyroid tumours may represent a very suitable type of
human tumour candidate for treatment with peritumoral or
intratumoral injection of antineoplastic drugs. In fact, due to its
late metastatic spreading, its severe local invasion and its relatively
easy accessibility from the outside, this tumour lends itself in an
ideal way to the peritumoral or intratumoral treatment such as the
one described in this paper. Finally, it is important to consider that
there are indeed already studies in the literature concerning
clinical trials of human gliomas treated by using peritumoral or
intratumoral injections of suicide and cytokine genes (Palu ` et al,
1999). It is interesting to note that a phase I clinical trial has been
conducted by the same group for the treatment of human
anaplastic thyroid carcinomas with peritumoral or intratumoral
injections of the same genes (Palu `, personal communication).
In conclusion, the dimeric RNases can be considered as drugs
suitable for the development of novel alternative therapeutic
agents against anaplastic thyroid tumours, to overcome the poor
responsiveness of this type of tumour to conventional chemother-
apeutic drugs, such as doxorubicin.
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